IntelliPharmaCeutics Int'l. (IPCI) Stock Spikes on Positive Non-Abusive Oxycontin Development

NEW YORK (TheStreet) -- IntelliPharmaCeutics International (IPCI) shares are up 17.7% to $3.19 in morning trading on Thursday after the Canadian drug manufacturer announced plans to accelerate the development program for its experimental generic anti-abuse oxycodone drug Rexista.

The company announced plans to accelerate development after receiving correspondence from the Food and Drug Administration saying that the company could skip phase III testing of the drug if it can prove bioequivalence to oxycontin. 

"We are thrilled with the FDA's positive acknowledgement, which enables us to accelerate the development and commercialization of our abuse deterrent Rexista Oxycodone XR product candidate. The avoidance of a Phase III trial eliminates a significant financial hurdle. More importantly, it shortens the development timeline and potential time to market," said CEO and co-founder Dr. Isa Odidi.

Oxycontin is a popular narcotic pain reliever used to alleviate moderate to severe pain in patients and is an extremely addictive opioid. An abuse-deterent version of the drug would be an attractive alternative for people with prior drug abuse problems.

The company said that it believes the phase I tests its conducted on Rexista do show bioequivalence to oxycontin and the company is therefore confident that it will be able to skip phase III tests per the FDA's recommendation.

TheStreet Ratings team rates INTELLIPHARMACEUTICS INTL as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

IPCI Chart IPCI data by YCharts

More from Markets

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump